Table 1.
Clinicopathological characteristics according to WHO 2016 molecular subgrouping of gliomatosis cerebri. Bold indicates statistically significant (P < 0.05). Abbreviations: IDHwt = IDH‐wildtype; IDHmt = IDH‐mutant; OS = overall survival.
| Total | IDHwt subgroups | IDHmt subgroups | P | |||||
|---|---|---|---|---|---|---|---|---|
| II | III | IV | II | III | IV | |||
| N = 89 (%) | n = 15 (16.9%) | n = 47 (52.8%) | n = 3 (3.3%) | n = 7 (7.9%) | n = 15 (16.9%) | n = 2 (2.2%) | ||
| Sex | 0.927 | |||||||
| Male | 52 (57.4) | 9 (60.0) | 27 (57.4) | 1 (33.3) | 5 (71.4) | 9 (60.0) | 1 (50.0) | |
| Female | 37 (41.6) | 6 (40.0) | 20 (42.6) | 2 (66.7) | 2 (28.6) | 6 (40.0) | 1 (50.0) | |
| Age (year) | 0.794 | |||||||
| <18 | 5 (5.6) | 1 (6.7) | 4 (8.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| ≥18 | 84 (94.4) | 14 (93.3) | 43 (91.5) | 3 (100) | 7 (100) | 15 (100) | 2 (100) | |
| OS† time (month) | 23 | 25 | 18 | 15 | 24 | 58 | 43 | 0.078 |
| 1 year‐OS rate | 78.7% | 73.3% | 72.3% | 100% | 85.7% | 93.3% | 100% | 0.433 |
| 2 year‐OS rate | 43.8% | 53.3% | 31.9% | 33.3% | 42.9% | 66.7% | 100% | 0.104 |
| 3 year‐OS rate | 25.8% | 20.0% | 17.0% | 33.3% | 28.6% | 46.7% | 100% | 0.044 |
| 1p/19q | 0.060 | |||||||
| Co‐deletion | 3 (3.4) | 0 (0.0) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (50.0) | |
| No codeletion | 86 (96.6) | 15 (100) | 45 (95.7) | 3 (100) | 7 (100) | 15 (100) | 1 (50.0) | |
| ATRX (n = 73) | <0.001 | |||||||
| Intact | 59 (80.8) | 13 (92.9) | 38 (95.0) | 1 (100) | 2 (40.0) | 5 (41.7) | 0 (0.0) | |
| Loss | 14 (19.2) | 1 (7.1) | 2 (5.0) | 0 (0.0) | 3 (60.0) | 7 (58.3) | 1 (100) | |
| TERTp (n = 34) | 0.626 | |||||||
| Wildtype | 27 (79.4) | 5 (100) | 11 (73.3) | 1 (100) | 2 (100) | 7 (77.8) | 1 (50.0) | |
| Mutated | 7 (20.6) | 0 (0.0) | 4 (26.7) | 0 (0.0) | 0 (0.0) | 2 (22.2) | 1 (50.0) | |
| P53 (n = 27) | 0.103 | |||||||
| Positive | 12 (44.4) | 1 (20.0) | 4 (28.6) | 1 (100) | 2 (100) | 3 (75.0) | 1 (100) | |
| Negative | 15 (55.6) | 4 (80.0) | 10 (71.4) | 0 (0.0) | 0 (0.0) | 1 (25.0) | 0 (0.0) | |
| Galectin‐3 (n = 20) | 0.230 | |||||||
| Positive | 6 (30.0) | 1 (20.0) | 5 (55.6) | ‐ | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Negative | 14 (70.0) | 4 (80.0) | 4 (44.4) | ‐ | 2 (100) | 3 (100) | 1 (100) | |
| Pleomorphic cells | 0.038 | |||||||
| Absent | 68 (76.4) | 15 (100) | 30 (63.8) | 2 (66.7) | 7 (100) | 12 (80.0) | 2 n | |
| Present | 21 (23.6) | 0 (0.0) | 17 (36.2) | 1 (33.3) | 0 (0.0) | 3 (20.0) | 0 (0.0) | |
†
OS time indicates median survival time.